Vir Biotechnology Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Welcome back, everyone, to the 3rd Annual HC Wainwright HBV Conference. My name is Patrick Trucchio. I'm a Senior Biotech Analyst at HC Wainwright. It's my pleasure to introduce our next presenters.
We have Howard Horn, CFO; Carey Hwang, Senior VP of Clinical Research and Head of Chronic Infection; and Phil Pang, Chief Medical Officer of Vir Biotechnology, a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technology to treat and prevent serious infections disease.
So maybe we can start first with some background on Vir including the founding of the company, what makes its platform unique and differentiated in the area of infectious disease.
Well, so Patrick, I think that's a great place to start, because I think that what we've seen over the last few years is that infectious diseases truly are one of the greatest threats to health, economic security, and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |